Blog
Is FDA's annual new drug count a nothingburger?
FDA approved 46 new drugs so far in 2017. But are they the drugs we need?
Did “Medicus economicus” kill Medicare Part B reform?
It's surprisingly hard to figure out how much oncologists make from office-infused drugs, but we gave it our best shot.
The myth of “leaner and meaner” pharma
Pharma CEOs boast of trimming headcount and boosting productivity. Spoiler alert: they're not.
Biotech and medtech pitch decks: The best guides, tips, and tricks
The best pitch deck resources and guides for biotech and medtech entrepreneurs (updated 7/30/2022).
Pharma's not so stingy with R&D after all
Critics claim pharma is skimping on research spending - but the data say otherwise.
New data in the FDA deregulation debate
Should FDA automatically approve drugs available in other countries? The potential clinical benefits may be overstated.
Why Pharma Undervalues Novel R&D
New data on drug ramp rates could increase the financial attractiveness of “pioneer” projects.
Will tough biotech IPO market catalyze pharma deals?
We found 31 Phase 2 assets that could be deal targets if private biotechs can't access public capital - but only for pharmas that can stomach a little risk.
Finally, A Pharma CEO Takes The High Road On Drug Pricing
Brent Saunders of Allergan shows pharma how it's done.
Calculating The Value Of An EpiPen
A timely test case for the math behind "value-based pricing".